San Diego Business Journal

Six San Diego County life science firms reported quarterly earnings and corporate updates.

Viking Therapeutics Inc., a biopharmaceutical company working on therapies for metabolic and endocrine disorders, reported a net loss of $7.9 million for the second quarter of 2015, compared with a net loss of $22.8 million in the same period last year.

The significant decrease in net loss was primarily due to the company recording a $21.2 million estimated license fee liability during the second quarter of 2014.

Neothetics Inc., a maker of cosmetic pharmaceutical therapies, reported a net loss of $9.5 million in the second quarter of this year, compared with a $2.3 million net loss in the same period last year.

The increase in net loss reflects the expenses related to conducting the Phase 3 trials for LIPO-202 AbCountour1 and AbContour2, as well as the planning and launch of two supplemental clinical studies.

Otonomy Inc., a company that makes treatments for the middle and inner ear, reported a net loss of $12.5 million for the second quarter of 2015, compared with a net loss of $10.2 million for the second quarter of 2014.

Research and development expenses for the second quarter of 2015 were $7.3 million, compared with $8.3 million for the second quarter of 2014. The decrease was a result of lower clinical trial-related expenses.

Pfenex Inc., a clinical-stage biotech that makes biosimilars, reported a net loss of $6 million in the second quarter of 2015, compared with a net loss of $2.2 million in the same period last year.

The increased spending was due to R&D expenses involved with the company’s product candidates PF708 and PF530, along with the hiring of additional R&D personnel.

aTyr Pharma Inc., a public biotherapeutics company addressing rare diseases, reported a net loss of $11.1 million in the second quarter of 2015, compared with a net loss of $5.6 million in the same period last year.

Research and development expenses were $7.5 million for the quarter ended June 30, 2015, compared to $3.6 million for the same period in 2014. The increase was primarily due to an additional $2.7 million in clinical development and manufacturing costs associated with Resolaris franchise activities, and $900,000 in expenses resulting from increased headcount, including $400,000 in non-cash stock-based compensation.

Mast Therapeutics Inc., a clinical stage biopharmaceutical company, reported a net loss of $10.2 million for the second quarter of 2015, compared with a net loss of $7.2 million for the same period last year.

Research and development expenses for the second quarter of 2015 were $7.7 million, compared to $4.8 million for the same period in 2014. The increase was due primarily to increases of $1.9 million in external nonclinical study fees and expenses, $800,000 in external clinical study fees and expenses and $200,000 in personnel expenses.